Patient-Specific Cancer Immune Cell Therapy for Brain Tumors Promising as Adjunctive Therapy

Sunday, March 01, 2009 Newport Beach, Calif. – Hoag Hospital announced encouraging clinical study results for the instillation of a patient-specific cancer immune cell therapy as an adjunctive treatment for glioblastoma multiforme (GBM). The non-randomized, phase 2 study concluded that intralesional therapy with autologous lymphokine-activated killer (LAK) cells is safe and the survival sufficiently encouraging … Read More